Non-Injectable COVID-19 Vaccine Starts Trial

Illustration (Unsplash)

JAKARTA - Australia has started to innovate a sophisticated COVID-19 vaccine without having to inject it into the recipient's body. This non-injectable vaccine is now starting to be tested.

The phase 1 COVALIA vaccine trial was held simultaneously in 3 places, namely Scientia Clinical Research in Sydney, Telethon Kids Institute in Perth, and Women's and Children's Hospital in Adelaide. This gene-based vaccine uses the DNA sequence of the SARS-CoV2 virus.

If it is not injected, then how does the vaccine get into the body?

Reporting from News.com Australia, Tuesday, June 29, this vaccine does not use an injection, but a jet spray or high-pressure spray. When it's sprayed with high pressure, the vaccine will penetrate into the skin and will be absorbed by body cells. Then the DNA code will produce proteins that trigger the body's immunity.

Previously, this spray vaccine technology has been used in America but has only been tested in Australia. The trial is being led by the University of Sydney.

The COVALIA vaccine was designed by the biotechnology company Technovalia and its partner BioNet who developed the DNA vaccine.

In phase one of the trial, 150 volunteers were required. Each person is given 2 doses of the vaccine with an interval of 1 month. If successful, it will continue with phase 2.

"This COVALIA study is an important milestone", said lead researcher at the University of Sydney, Nicholas Wood.